Strategic shift from Italy to India strengthens supply chain resilience, expands capacity and enhances sustainability for the growing global UDCA market
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
Broadening access for children & patients with inhibitor-complicated hemophilia
Deal expands SPI Pharma’s manufacturing footprint in Germany, enhances pharmaceutical ingredient offerings, and reinforces focus on fast-growing digestive health market
Collaboration combines Lupin’s inhaler manufacturing capabilities with ERN’s strong commercial presence to expand access to respiratory care
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Subscribe To Our Newsletter & Stay Updated
